MEDICINAL COMPOSITION AND METHOD OF MAKING SAME

Abstract: A drug delivery system for delivering a pharmaceutical to the brush layer of the small intestine for absorption through the brush layer and for direct passage into the thoracic duct without digestion or breaking up in the stomach and with neither interception by nor reaction with the bile salts of the digestive system. The system involves the formation of an emulsion of oil globules predominantly less than about 1000 Å in diameter in which the pharmaceu­ tical is contained, either dissolved in the oil or dispersed therein in water solution, and the integrity of each globule is maintained by an encasing water layer firmly held in place by surface tension. As a part of the system and to insure proper delivery and protection of the emulsion, e.g. for shelf life and delivery to the stomach the emulsion is mixed wth a water absorbent powder, such as dextran, and the powder is encapsulated in a conventional gelatin capsule. The techni­ que of making the emulsion, of forming a solid composition for filling the capsule, and the composite capsule itself are all disclosed, as well as the unique drug delivery system.

Description: MEDICINAL COMPOSITION AND METHOD OF MAKING SAME BACKGROUND OF THE INVENTION As well pointed out in the literature, e.g. Drug Absorption, Chapter 53, pages 130-137, Gastroenterology Volume 2, Third Edition, W. B. Saunders Company, Philadelphia, Penn., 1976; and in the Lancet, November 10, 1979, pages 1003, 1004, drug absorption by the human body is a very complex affair which is subject to many upsetting factors. Some orally ingested drugs cause irritation of the gastric and intestinal mucosa, or are destroyed by acid or enzymes in the digestive tract, or react with other drugs food materials. Some quite useful drugs are limited by their toxic effect on the body when utilized in therapeutic dosages, e.g. vitamin A in its various forms causes hepatitis and other liver. ailments when administered in large amounts by conventional delivery means, including intraveneous feeding. Yet, it has been found that retinoids, i.e. the various forms of vitamin A, can be useful to arrest or reverse the progression of premalignant cells and thus to delay or prevent the development of invasive znaligndncy, Spron et al, Prevention of Chemical Carcinogenesis by Vitamin A and Its -Synthetic Analogs, 'Federation of American Societies for Experimental Biology, Federation Proceedings, 35: 1332-1338, 1976; and Sporn et al, Chemoprevention of Cancer with Retinoids, Federation Proceedings, 38: 2528-2534, 1979. Other studies have reached similar conclusions. A recent incomplete and unreported research study indicates possible activity df vitamin A palmitate in the reactivation lymphocytes. In early cancer patients, responsive lymphocytes will migrate to attack the tumor cell; whereas in later states of cancer the lymphocyte is unable to migrate to attack the tumor cell. After treatment with vitamin A palmitate, C36H6002, there is an indication that the lymphocyte regains responsiveness and again attacks the tumor cell. It is well known that the delivery of lipid-soluble drugs, such as vitamin A palmitate follows the normal course of fat digestion and absorption, involving emulsification, hydrolysis, absorption and chylomicron transport, requiring passage through the liver. Vitamin A palmitate is lipid-soluble and can be administered orally in an oil as a solvent. After passage through the stomach, the drug is assailed by the bile acids, converted by hydrolysis, and re-esterified during uptake and storage of vitamin A by the liver, see Smith and Goodman, Nutrition Reviews' Present Knowledge in Nutrition, pages 64-72, Fourth Edition, The Nutrition Foundation, Inc., N.Y., Washington, 1976. For vitamin A palmitate when taken orally to enter the blood stream, the drug must be acted upon by. the bile acids, hydrolyzed to a different form, reduced to a critical size (less than 1000 A), passed through the brush layer of the small intestines and passed through the liver. If the drug is not acted upon swiftly by the bile acids or if it is not reduced to the critical size, then it passes on through the intestine. For these and other reasons (such as delayed re-esterification in the liver), the effective dosage of the drug actually delivered to the thoracic duct upon normal oral ingestion varies from patient to patient and from time-to-time for each patient. If it were possible to deliver lipid-soluble drug directly to the blood stream, then therapeutic dosages of such drugs as vitamin A palmitate would become possible without the dangers of the normal delivery system, such as liver damage, and such delivery will be more efficient, more predictable and relatively free of side effects. If such a system, in addition, were capable of delivering water soluble drugs, such as ferrous sulfate or potassium chloride, then the same improved therapeutic effects could be obtained while minimizing the side effects of such drugs. BRIEF DESCRIPTION OF THE PRESENT INVENTION The present invention now proposes a solution to the problem of delivery of retinoids (typically vitamin A palmitate) and other pharmaceuticals to the body. The delivery system of the present invention specifically involves the delivery of a drug dispersed in oil droplets of extremely minute size (predominantly less than 1000 A in diameter) and in unchanged form to the brush layer of the small intestine for absorption directly into the thoracic duct and hence into the blood system. While the system of the present invention is well adapted to delivery of retinoids, as hereafter explained in detail, it can also serve to deliver other drugs, whether lipid-soluble or water-soluble. The desired drug is dispersed in the oil, either by solution in the case of lipid-soluble drugs or by forming a water-in-oil emulsion in the case of water-soluble drugs, by an emulsion technique. The emulsion is formed of the oil containing the drug, water and a surfactant, preferably in a ratio of about one part surfactant, two parts water, and four parts oil, with the ingredients being mixed and homogenized to form an emulsion in which the minute oil droplets are each surrounded by an enveloping layer of water which is tenaciously held in position by the surface tension of the water itself. The emsulsion then preferably is mixed with and distributed throughout a mass of solid powder, preferably a low molecular weight polysaccharide, with each droplet or globule of oil retaining its own identity and size. The powder is then encapsulated for ingestion. Alternatively, the capsule can be lined with the polysaccharide, and the emulsion can then be poured or otherwise introduced into the lined capsule. In either case, the polysaccharide serves a multiplicity of functions, i.e. to maintain the integrity of the surrunding capsule by absorbing the water of the initial emulsion, to prevent the invasion of ambient moisture during storage of the capsules, to promote shelf life of the emulsion, etc. Once ingested, the gelatin capsule and the polysaccharide are digested or broken down in the stomach and the released oil globules with the pharmaceutical therein pass unaltered through the stomach and into the small intestine. Apparently, the minute oil droplets are presented to the brush layer of the small intestine in unaltered form for passage directly therethrough into the thoracic duct. Since vitamin A palmitate, for example, when delivered as herein proposed, does not hydrolyze in the bile acids and does not require re-esterification in the liver, the drug in effect by-passes the liver. The advantages will be evident. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT OF THE INVENTION The emulsion of this invention comprises oil droplets or globules of a size predominantly less than 1000 A in diameter and preferably ranging from about 500 to about 1000 Angstroms (A), i.e. from about 0.05 to about 0.1 microns, within which the administered drug is present. It has been determined experimentally that the techniques here proposed result in an emulsion which contains predominantly (on the order of 70%) globules of a size corresponding to 1000 or less. While the exact delivery mechanism is not known at this time, it appears that globules of this size do not excite or trigger the enzyme bile action of the body. Thus, oil globules of the fine micellar size contemplated by this invention can be delivered without change from the stomach and can be directly absorbed at the brush layer of the small intestine for passage directly into the thoracic duct and therefore directly into the blood system for systemic circulation. The importance of such direct absorption can be appreciated for example in vitamin A therapy. Retinoids, such as vitamin A palmitate, C36H6002, when dissolved in oil globules of such size, can -in effect -- by-pass the liver, with the retinoid passing undisturbed and in pristine condition through the stomach, through the brush layer of the small intestine and directly into the thoracic duct. Since such saturated retinyl esters (previously formed for therapeutic purposes only upon reesterification in the liver) are transported into the body through the lymphatic route, the presentation of vitamin A palmitate to the thoracic duct through the technique of this invention yields the desired therapeutic agent at the desired location without passage through the liver. The same benefits of exact drug delivery in precise dosages at the most beneficial place can be obtained for other drugs in essentially the same fashion, whether such drugs are lipid-soluble or watersoluble. The emulsion also comprises an enveloping layer of water surrounding each oil globule. This water layer can be observed microscopically, and it serves to prevent agglomeration of the oil particles into a single mass, once the emulsion has been formed. The water layer is formed and retained by the surface tension of the water component of trie emulsion, and persists as the emulsion passes through the stomach and is presented to the brush layer of the intestine. While the absorption mechanism at the brush layer is not fully known at this time, there is reason to believe that the water layer is stripped away either immediately prior to or during passage of the globule through the intercellular space of the brush layer itself. The pharmaceutical component of the emulsion is dissolved directly and in the desired dosage in the initial oil component in the case of lipid-soluble substances, such as vitamin A palmitate, procarbazine, and BCNU (bis-chloroethyl nitrosourea). Where the pharamaceutical component is water soluble, such as ferrous sulfate or potassium chloride, the desired dosage amount of the pharmaceutical is dissolved in water distributed internally of the oil globules during the formation of the emulsion by an emulsion inversion technique. The water soluble drug is first mixed with the oil phase, then the surfactant is added, followed by the water, so that the drug then preferentially dissolves into the water aided by the surfactant. The result is a water-in-oil emulsion obtained by an emulsion inversion technique, with the water containing the drug, and sufficient water is present to retain the enveloping water layer on the oil globules. This exterior water may contain some of the drug, but it makes no difference in the final result, since the water layer persists, at least until the brush layer is reached. The surfactant is presently believed necessary to the formation of the fine emulsions of this invention. Where the surfactant was not present, the oil globules predominantly were larger than the desired size, varied substantially in size, and tended to separate or layer upon standing. Even processing non-surfactant emulsions through a centrifuge resulted in globules ranging from about o o 1,000 A to about 10,000 A. The surfactant itself preferably is a natural gum, such as gum arabic, gum tragacanth, or the like. In the use of gum tragacanth, larger amounts of emulsion water are required, on the order of ten times the amount required for the use of gum arabic. Gum arabic normally includes an enzyme which preferably is destroyed by heating the gum to a temperature of about 800C prior to its use in the present invention. It is possible to use synthetic surfactants, although they have some tendency to crystallize, which may cause some problems with the retention of the water layer enveloping the oil globules. For these reasons, gum arabic is the presently most preferred surfactant, and natural gum-type surfactants are preferred, although other surfactants including synthetic materials, such as "Tween" (a product of ICI United States) can be utilized, if desired. The oil utilized is preferably a vegetable oil, such as corn oil, olive oil, peanut oil, castor oil, sesame oil or the like, or a fish oil, such as fractionated salmon oil. Since the oil acts as the carrier for the pharmaceutical, it must pass through the stomach without dissolution or digestion, and any oil capable of forming the desired emulsion, and which has the desired degree of inertness and is not toxic to the body can be utilized. The presently most preferred emulsion of the present invention -- utilizing gum arabic, sterile water and sesame oil -- contains these ingredients in a ratio of about 1:2:4, with the drug present at the chosen concentration. Where gum tragacanth is utilized as a surfactant, the preferred proportions are about 1:20:40. The emulsion can be formed by a simple mortar and pestle manual manipulation, as shown by the following examples. Commercially, any desired emulsifying and homogenizing apparatus can be used. A homogenizer of the Gaulin type is preferred, and such a homogenizer having a very small high pressure orifice through which the emulsion is forced at pressures up to 10,000 psi can be utilized. Centrifugal emulsifiers or homogenizers can also be used, but it is difficult to produce the extremely finely divided emulsions of the present invention in commercial quantities in centrifugal apparatus. Once the emulsion is formed, consisting of the oil globules in water with each globule bearing its adherent water film, the emulsion is admixed with a solid powder to form a coherent, moldable or formable mass in which the individual oil globules are distributed. Alternatively, the emulsion in bulk can be encapsulated within the powder by a technique hereafter described. The preferred powder is a low molecular weight polysaccharide, and the most preferred polysaccharide is dextran of an average 40,000 daltons, ranging from about 10,000 to about 80,000 daltons. Other polysaccharides can be utilized, such as commercially available cornstarch. Heta starch or hydroxyethyl starch can also be utilized as the solid powder. The purpose of the powder is to provide an osmotic pressure substance which is capable of picking up the excess water from the initial emulsion, where the excess water is defined as that in excess of the total water present in the enveloping water layer surrounding each oil globule plus any water emulsified in the oil where a watersoluble drug is present. Further, the powder will absorb any water which might invade the capsule during storage of the emulsion prior to use and any water which might interfere with encapsulation of the emulsion in a water-soluble capsule. The powder is added in an amount in excess of the amount of the emulsion, typically about four (4) times as much powder. In the final emulsionpowder composite, the powder preferably will constitute from about 75 to about 95% of the total volume, and most preferably from about 80% to about 90%. In one version of the invention, the emulsion, as finally formed, is sprayed over or otherwise introduced into admixture with the dextran or other powder which has been placed in a mixing bin. The bin contains a rotatable double ribbon agitator with millers to prevent lumping or particle re-aggregation. After the desired pharmaceutical concentration of emulsion is attained, the mixing is halted. The powder picks up the excess water from the emulsion, and the composite appears to be a solid, firm mass which is almost rock-like. When the mass is broken into a powder and is microscopically observed, it will be seen that the individual drugcontaining oil globules are still present, each globule with its own water surface coating. The composite powder can be molded to a capsule-filling shape, or the loose powder can be used to fill a capsule in the conventional manner. Alternatively, the powder (preferably dextran) can be sprayed into the open halves of a capsule to form a coating or layer on the interior thereof, and the liquid emulsion can be poured into one half of the lined capsule and covered with the other half. In either version of the invention, the emulsionopowder composite may be encapsulated into a conventional gelatin capsule or other stomachsoluble enclosure. If the emulsion alone were enclosed in the capsule, the capsule would dissolve or disintegrate in the water present in the emulsion. The powder makes possible the encapsulation of the emulsion, protects the emulsion from any moisture entering the capsule during storage, and at the same time preserves the essential character of the emulsion, per se. The encapsulation technique of the present invention enhances the stability of lipid-soluble drugs sufficiently to ensure Federal Drug Administration approval, protects the drug, whether lipid-soluble or water-soluble, from oxidation or light (where the capsule is opaque), insures exact dosage compliance, and assures delivery of the my cellar globules and the drug present therein to the brush layer in unaltered form. After ingestion of the capsule, the gelatin outer layer dissolves in the stomach, and the powder is digested or broken down in the stomach. For example, dextran is broken down to fructose. EXAMPLE I Preparation of Emulsion 1 ml of gum arabic was placed in a mortar. 4 ml of sesame oil having 1 ml of Vitamin A palmitate (1,000,000 I.U.) dissolved therein was added to the mortar. The mixture was constantly stirred and worked with a pestle as 2 ml of sterile water was added to the mixture. After 30 minutes of stirring and working, the emulsion was observed under a microscope utilizing a micrometer scale. It was found that 70% of the globules were of a size less than 1000 , 50% were of a size less than 800 , and 1-2% were of a size less than 400 A. Each globule was encased in a layer of water adhered thereto by surface tension. EXAMPLE II Preparation of Powder To the 8 ml of product obtained as in Example I above, 32 ml by volume of low molecular weight dextran (average molecular weight 40,000 daltons, ranging from 10,000 to 80,000 daltons) was added to the mortar and mixed and worked until a homogeneous mixture was obtained. The final mixture had a gross appearance similar to a stone which would pulverize with pressure Upon microscopic examination, the emulsion was still present as minute globules with the surface layer of water intact on each oil globule. EXAMPLE III Examples I and II were repeated, with the substitution of BCNU (200 mg of dry powder) for the vitamin A palmitate. Identical results were obtained in the formation of the emulsion (Example I) and the solid mass (Example II). EXAMPLE 4 ml of sesame seed oil mixed with 300 mg of finery powdered ferrous sulfate was thoroughly mixed using a mortar and pestle. 1 cc of gum arabic was added as mixing continued, then 2 ml of water was added. After about 30 minutes of continuous mixing and working a finely divided emulsion was obtained. 28 ml of low molecular weight dextran was added and mixing was continued, all as in Example II. Upon microscopic examination, as in Example II, the same results were obtained; e.g. a dry powder in which emulsion globules of a size predominantly less than 1000 were present, each globule being surrounded by a surface water layer. EXAMPLE V Example was repeated, but substituting 400 mg of KC1 for the ferrous sulfate ingredient. The results obtained were identical with those of Example. EXAMPLE VI 20 male Swiss mice, each 6 months old, were divided into two groups, A and B, of 10 mice each. 0.1 mg of the emulsion of Example I was dropper-fed to each of the mice of Group A, 0.25 ml of Mugos product was fed by dropper to each of the mice of Group B. The dosage level fed each mouse was 125,000 international units of vitamin A palmitate. 60 minutes after feeding, each mouse was sacrificed by blood letting, utilizing the inner ca.,; us technique. Each blood sample was labeled and centrifuged. The serum of each sample was tested by high performance liquid chromotography to determine the vitamin A palmitate content. The results were as follows: GIwP A GROUP B Vitamin A Vitamin A Mouse palmitate content Mouse palmitate content 1 23 1 12 2 30 2 18 3 21 3 9 4 26 4 11 5 31 5 5 6 26 6 9 7 21 7 1l 8 18 8 4 9 30 9 7 10 29 10 5 Average 25. t Average 9.1 EXAMPLE VII Twenty patients were selected for a study. On a first day, each patient was given Musos vitamin A palmitate oil solution (containing sesame oil, gum arabic, and D-alpha-Tocophrol acetate and vitamin A palmitate). Each patient received a dosage of Mugos solution containing 10,000 International units of vitamin A palmitate at 09:00 hours. 3 ml of blood was withdrawn from each patient at 13:00 hours of the same day and again at 17:00 hours. The same 20 patients, on another day, were given capsules filled with the composition of Example II, and each containing 10,000 International units of vitamin A palmitate. The capsules were taken at 09:00 hours, and 3 ml of blood was withdrawn from each patient at 13:00 hours of the same day and again at 17:00 hours. The vitamin A palmitate content of each sample of each patient's blood was determined by liquid chromotography, and the following results were obtained. VITAMIN A PALMITATE CONTENT Mugos Sample Example II Sample Patient No. 13:00 Hours 17:00 Hours 13:00 Hours 17:00 Hours 1 3 1 5 2 2 1 0 7 2 3 1 0 5 3 4 2 0 5 2 5 1 0 3 0 6 3 0 8 3 7 1 0 7 3 8 1 0 7 3 9 2 1 8 2 10 1 0 5 1 1l 1 0 5 2 12 1 0 7 2 13 2 0 7 2 14 1 0 8 3 15 1 0 6 2 16 1 1 7 2 17 2 0 7 3 18 2 0 8 3 19 1 0 8 3 20 1 0 8 2 Average 1.45 0.15 6.6 2.25 It will be seen that after 4 hours, the composition of the invention placed an average of 4.55 times as much vitamin A palmitate in the blood, and after 8 hours, an average of 15 times as much. EXAMPLE Y'1t A primary emulsion was prepared as set forth in Example I above. The oil, pharamaceutical and surfactant ingredients were first emulsified with one-half of the water and then the remaining one-half of the water was added. The emulsion contained: INGREDIENT AMOUNT Vitamin A palmitate 3 grams Peanut Oil 2 grams Water 4 grams Gum arabic 1 gram The final emulsion was added slowly with a syringe to 42 grams of starch in a blender during rotation. The powder was removed from the blender and packed into capsules. 102 capsules were made, each containing 500 mg. of powder and each containing a unit dosage of 50,000 International units of vitamin A palmitate.

Claims: WHAT IS CLAIMED IS: 1. An orally ingestible medicinal composition capable of delivering a pharmaceutical in its unaltered original state to the brush layer of the small intestine, comprising a plurality of individual oil globules each enveloped within a surrounding layer of water adhered to the globules by surface tension and serving to retain the globules in independent droplet form, said globules being predominantly of a size less than about 1000 in diameter, a pharamaceutical component disposed within each globule, a water absorbent carrier powder preventing access of extraneous water to said globules while leaving intact the enveloping water layer, and a capsule within which said powder and said globules are retained for ingestion, said capsule and said powder being digestible or broken up in the stomach so that the oil globules and the pharmaceutical component therein pass unaltered into the small intestine. 2. A composition as defined in claim 1, wherein the pharmaceutical component is lipidsoluble and is dissolved in the oil globules. 3. 'A composition as defined in claim 1, wherein the pharmaceutical component is water soluble and is present in the oil globules as an emulsion of water in oil. 4. A composition as defined in claim 1, wherein the powder component is a polysaccharide of relatively low molecular weight on the order of an average 40,000 daltons. 5. A composition as defined in claim 1, wherein the oil is a vegetable oil. 6. A composition as defined in claim 1, wherein the oil is fractionated salmon oil. 7. A composition as defined in claim 1, wherein the composition also contains a natural gum surfactant. 8. A medicinal composition consisting essentially of a gelatin capsule containing from about 75 to 95% low molecular weight dextran and the balance a unit dosage of vitamin A palmitate dissolved in an oil which is emulsified with gum arabic and water, the gum arabic : water : oil ratio being about 1:2:4, and the oil being present as individual globules of a diameter predominantly less than 1000 . 9. A medicinal composition consisting essentially of a gelatin capsule containing from about 75 to about 95% low molecular weight polysaccharide and the balance being a unit dosage of a pharmaceutical present in an oil which is distributed in the polysaccharide as individual globules of a diameter predominantly less than about 1000 A. 10. A composition as defined in claim 9, wherein the pharmaceutical is lipid-soluble and is dissolved in the oil. 11. A composition as defined in claim 9, wherein the pharmaceutical is water soluble and is presented in the oil as a water-in-oil emulsion. 12. A method of making a medicinal composition comprising the steps of a. forming an emulsion consisting essentially of an oil having vitamin A palmitate dissolved therein, gum arabic and water, the ratio of gum arabic water : oil being about 1:2:4, b. homogenizing the emulsion to reduce the oil to globules having a diameter ranging from about 500 A to about 1000 , c. mixing the homogenized emulsion with a quantity of dextran powder equivalent to about four times the volume of the emulsion, and d. encapsulating in a gelatin capsule an amount of the emulsion-dextran mixture necessary to provide a desired unit dosage of vitamin A palmitate. 13. A method of making a medicinal composition comprising the steps of a. forming an emulsion consisting essentially of an oil having a pharmaceutical dispersed therein, a surfactant and water, b. homogenizing the emulsion to reduce the oil to individual pharmaceutical containing globules having a diameter predominantly less than 1000 ; c. mixing the homogenized emulsion with a quantity of a low molecular weight polysaccharide to provide a final mixture which is about 80-90% polysaccharide and the balance emulsion and in which the pharmaceutical containing globules are-unaltered; and d. encapsulating the mixture in individual dosage units to yield a desired dosage amount of the pharmaceutical. 14. A method as defined in claim 13, wherein the pharmaceutical is lipid-soluble and is dissolved in the oil. 15. A method as defined in claim 13, wherein the pharmaceutical is water-soluble and is present in the oil as a water-in-oil emulsion. 16. A method as defined in claim 13, wherein the surfactant is a natural gum. 17. A method as defined in claim 14, wherein the emulsion is formed by mixing the oil having the pharmaceutical dissolved therein with the surfactant, then adding the water with additional mixing. 18. A method as defined in claim 15, wherein the emulsion is formed by first mixing the water-soluble pharmaceutical with the oil, then adding the water and surfactant with additional mixing. 19. A method as defined in claim 13, wherein the surfactant : water : oil ratio is about 1:2:4. 20. A method as defined in claim 19, wherein the surfactant is gum arabic, the oil is a vegetable oil, and the polysaccharide is low molecular weight dextran present in an amount equal to about four times the amount of emulsion.

Inventors: TUCKER, WILLIAM GOUGH
Applicants: TUCKER, WILLIAM GOUGH
Application year: 1982
Main classification: A61K9
IPC codes: A61K9